| Entries |
| Document | Title | Date |
|---|
| 20080227957 | Reducing Immunogenicities of Immunoglobulins by Framework-Patching - Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described methods of humanization, which graft CDRs from a donor onto the frameworks of a single acceptor immunoglobulin, we patch segments of framework (FR1, FR2, FR3, and FR4), or FRs, to replace the corresponding FRs of the parent immunoglobulin. Free assortment of these FRs from different immunoglobulins and from different species can be mixed and matched into forming the final immunoglobulin chain. A set of criteria in the choice of these FRs to minimize or eliminate the need to reintroduce framework amino acids from the parent immunoglobulin for patching is described. The approach gives greater flexibility in the choice of framework sequences, minimizes the need to include parent framework amino acids, and, most importantly, reduces the chances of creating new T- and B-cell epitopes in the resultant immunoglobulin. | 09-18-2008 |
| 20080242843 | FUNCTION OF A HAPTOGLOBIN-HAEMOGLOBIN RECEPTOR AND THE USES THEREOF - The present invention relates to haptoglobin-haemoglobin (Hp-Hb) complex or a part thereof or a mimic thereof being operably linked to a substance and capable of binding a CD163 receptor. Furthermore, the invention relates to a CD163 variant, membrane bound or soluble, capable of binding at least one haptoglobin-haemoglobin (Hp-Hb) complex, and the use of the Hp-Hb complex and the CD163 receptor for therapy. | 10-02-2008 |
| 20080242844 | Ultra-high Yield Intravenous Immune Globulin Preparation - An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs one or more salts from a group of salts comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride in two initial fractionation steps, followed by diafiltration to remove those salts employed. A process which employs alcohol via the process of the disclosed inventive method is also disclosed. | 10-02-2008 |
| 20080249285 | Method For Affinity Purification - The invention relates to a method of immunoaffinity purification which comprises the use of a binding agent which binds to an epitope that it is present at least twice on the target molecule. In another embodiment the method uses at least two different binding agents, each binding to different epitopes on the target molecule | 10-09-2008 |
| 20080269464 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided. | 10-30-2008 |
| 20080269465 | BIOLOGICAL PRODUCTS - There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFα. | 10-30-2008 |
| 20080306246 | Process for Attaching Effector Molecules to Proteins - The present invention provides a process for attaching one or more effector molecules to one or more cysteines in a protein comprising: a) activating one or more cysteines in the protein by diafiltering the protein against a monothiol reducing agent or a multi-thiol reducing agent which is incapable of forming intramolecular disulphide bonds and b) reacting the treated protein with an effector molecule. | 12-11-2008 |
| 20080319172 | DEVICE FOR DETECTING MOLECULES, METHOD FOR DETECTING MOLECULES - A construct is provided that is capable of binding a plurality of molecules, the construct comprising a first moiety with a first molecule binding region and a first molecule non-binding region; and a second moiety with a second molecule-binding region and a second molecule-non-binding region, whereby the first binding region and second binding region are at opposite ends of the construct. Also provided is a method for detecting protein having certain amino acid sequences, the method comprising supplying a collection of proteins each with unknown amino acid sequences, contacting the collection with a moiety having a plurality of binding sites capable of binding with the protein having certain amino acid sequences so as to form a moiety-protein complex, and mixing the complex with a marker specific for the moiety in an amount sufficient to indicate existence of the complex | 12-25-2008 |
| 20090012267 | ANTI-HYDROXYLASE ANTIBODIES AND USES THEREOF - Antibodies, or antigen-binding portions thereof, to aspartyl (asparaginyl) β-hydroxylase are provided. The anti-aspartyl (asparaginyl) β-hydroxylase antibodies, or antigen-binding portions thereof, can modulate activity of aspartyl (asparaginyl) β-hydroxylase. | 01-08-2009 |
| 20090062514 | PLANT VIRAL PARTICLES COMPRISING A PLURALITY OF FUSION PROTEINS CONSISTING OF A PLANT VIRAL COAT PROTEIN, A PEPTIDE LINKER AND A RECOMBINANT PROTEIN AND USE OF SUCH PLANT VIRAL PARTICLES FOR PROTEIN PURIFICATION - A process of purifying a protein of interest using viral particles or virus-like particles comprising a plurality of fusion protein molecules, said fusion protein comprising the following fusion protein domains: (i) a plant viral coat protein, (ii) a recombinant protein, and (iii) optionally a peptide linker linking said plant viral coat protein and said recombinant protein, wherein formation of said viral particle does not require free viral coat protein. | 03-05-2009 |
| 20090076247 | HIGH PRESSURE REFOLDING OF MONOCLONAL ANTIBODY AGGREGATES - Methods for refolding antibodies, particularly monoclonal antibodies, from aggregated and/or denatured preparations by subjecting the antibody preparation to high hydrostatic pressure are provided. Refolded preparations of antibodies produced by the methods described herein are also provided. | 03-19-2009 |
| 20090082548 | SYSTEM AND METHOD FOR PRODUCTION OF ANTIBODIES IN PLANT CELL CULTURE - A system and method for production of antibodies in plant cell culture, which results in highly functional antibodies, produced with a high level of expression efficiency. The present invention also encompasses host cells, vectors and methods for mass production of full size assembled immunoglobulins. | 03-26-2009 |
| 20090093617 | Crystals of whole antibodies and fragments thereof and methods for making and using them - This invention relates to crystals of whole antibodies and fragments thereof, and formulations and compositions comprising such crystals. More particularly, methods are provided for the crystallization of high concentrations of whole antibodies, and fragments thereof, in large batches, and for the preparation of stabilized whole antibody crystals for use alone, or in dry or slurry formulations or compositions. This invention also relates to methods for stabilization, storage and delivery of biologically active whole antibody crystals. The present invention further relates to methods using whole antibody crystals, antibody fragment crystals, or compositions or formulations comprising such crystals for biomedical applications, including biological delivery to humans and animals. More particularly, whole antibody crystals or antibody fragment crystals, or crystal compositions or formulations thereof, are used as a carrier-free delivery system which can slowly release active whole antibodies or fragments thereof, to a subject, where and when they are needed. | 04-09-2009 |
| 20090099339 | ANTIBODY AND ANTIBODY FRAGMENTS FOR INHIBITING THE GROWTH OF TUMORS - Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors. | 04-16-2009 |
| 20090118472 | Biomarkers for toxic algae - The present invention is directed toward biomarkers that identify characteristics of algae. The invention is further directed toward biomarkers that serve to identify algae species and strains of algae species as well as detect the presence of algal toxins. Additional embodiments feature methods utilizing algal biomarkers and polypeptides that can serve as biomarkers. | 05-07-2009 |
| 20090143569 | BACTERIOLYTIC AGENT - The present invention is a bacteriolytic agent containing a cationic surfactant (A) of which a counteranion is an acid having a pKa (25° C.) of 0 to 10. As the counterion, a carboxylate anion is preferable. As the cationic surfactant (A), a quaternary ammonium salt-type surfactant is preferable. Examples of the useful substance include a protein, an amino acid, a nucleic acid, an antibiotic, sugars or vitamins. | 06-04-2009 |
| 20090156787 | ANTIBODY PRODUCTION ELICITED BY A DNA VACCINE DELIVERED BY ELECTROPORATION - There are provided methods of generating antibodies in a mammal against recombinant antigens using DNA plasmids capable of expressing said antigens in cells of said mammal, comprising: injecting into tissue of said mammal a DNA plasmid comprising an encoding sequence operably linked to a promoter, electroporating said tissue with an electroporation device capable of delivering an electrical pulse effective to electroporate cells of said tissue to allow entry of said DNA plasmid and expression of said antigen, and allowing said mammal to respond to said expressed antigen in order to generate antibodies to said antigen. Furthermore, there are provided methods of isolating antibodies specific against desired antigens wherein said antibodies are generated in a mammal using DNA plasmids capable of expressing said antigens. | 06-18-2009 |
| 20090163698 | Method for Preparing Antibody Conjugates - The subject matter described herein relates to a process for preparing an antibody, in one embodiment a Fab′, in very good yields and purity, under conditions where the presence of heavy and light chain antibody fragments is minimized. More particularly, the subject matter described herein relates to a process for reducing F(ab) | 06-25-2009 |
| 20090215991 | Optimized Fc Variants and methods for their generation - The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 08-27-2009 |
| 20090221801 | Adsorbents for Protein Purification - Use of an affinity adsorbent for the separation, removal, isolation, purification, characterisation, identification or quantification of a proteinaceous material, wherein the affinity adsorbent is a compound of formula (III), wherein R | 09-03-2009 |
| 20090253899 | RECONSTITUTED POLYPEPTIDES - The present invention provides modified fibronectin type III (Fn3) molecules, and nucleic acid molecules encoding the modified Fn3 molecules. Also provided are methods of preparing these molecules, and kits to perform the methods. | 10-08-2009 |
| 20090270596 | CHROMATOGRAPHY PURIFICATION OF ANTIBODIES - Methods, kits and apparatuses for chromatography purification of antibodies are provided. In some embodiments, antibodies are purified by mixed mode chromatography that does not comprise hydroxyapatite (HT) or fluorapatite (FT). The mixed mode chromatography step is then followed by a HT/FT chromatography step. | 10-29-2009 |
| 20090281284 | GOLD-BINDING PROTEIN AND USE THEREOF - A protein utilizing an anti-gold antibody and a gold-binding side which is a part of the anti-gold antibody is constructed. This protein is capable of specifically binding to gold. This protein or a complex protein containing such a protein can be used for the detection of a target substance. | 11-12-2009 |
| 20090281285 | BINDING MEMBER WHICH BINDS TO BOTH LEWIS-Y AND LEWIS-B HAPTENS, AND ITS USE FOR TREATING CANCER - The invention relates to the use of a binding member which binds to Lewis | 11-12-2009 |
| 20090306347 | ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR PRODUCTION THEREOF - Disclosed is an antibody produced using an ostrich. Also disclosed is a method for producing the antibody. By using an ostrich, it becomes possible to produce antibodies (particularly antibodies for medical use), which have been hardly produced by using the mammals such as the mouse and the rat, homogeneously in a single body, in large quantities and in a simple manner. The method can overcome a disadvantage of lot-to-lot variation which may occur in the production of polyclonal antibodies using other animals. | 12-10-2009 |
| 20090326202 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 12-31-2009 |
| 20100004429 | AGONIST ANTIBODY TO HUMAN THROMBOPOIETIN RECEPTOR - This invention provides an agonist antibody to a human thrombopoietin receptor (alias: human c-Mpl). More particularly, this invention provides an agonist antibody to a human thrombopoietin receptor, wherein the agonist antibody comprises: antibody constant regions comprising (1) amino acid sequences in a heavy chain constant region and a light chain constant region of a human antibody, (2) an amino acid sequence of a heavy chain constant region with a domain substituted between human antibody subclasses, and an amino acid sequence of a light chain constant region of a human antibody, or (3) amino acid sequences comprising a deletion(s), substitution(s), addition(s), or insertion(s) of one or several amino acid residues in the amino acid sequences of (1) or (2) above; and antibody variable regions capable of binding to and activating a human thrombopoietin receptor; and wherein the agonist antibody has the properties: (a) that the antibody induces colony formation at a concentration of 10,000 ng/ml or lower as determined by the CFU-MK colony formation assay using human umbilical-cord-blood-derived CD34+ cells; and (b) that the antibody has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less in the cell proliferation assay using UT7/TPO cell. Also provided is a pharmaceutical composition for treating thrombocytopenia comprising said antibody. | 01-07-2010 |
| 20100010199 | MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS - Currently, the steps performed prior to release of influenza strains to vaccine manufacturers involve passaging influenza virus through eggs. The invention aims to provide procedures useful in manufacturing influenza vaccines, in which the use of eggs is reduced, and preferably is avoided altogether. For instance, rather than use chicken eggs for influenza vaccine isolation, MDCK cells (Madin Darby canine kidney cells) may be used e.g. growing in suspension, growing in a serum-free medium, growing in a protein-free medium, being non-tumorigenic, grown in the absence of an overlay medium, etc. | 01-14-2010 |
| 20100016555 | N-Acetylglucosaminyltransferase III Expression in Lower Eukaryotes - The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII activity, which produce bisected N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained. | 01-21-2010 |
| 20100022756 | Trimerising Module - The present invention relates to the design of trimeric polypeptides using polypeptide structural elements derived from the tetranectin protein family, and their use in rational de novo design and production of multi-functional molecules including the application of the multi-functional molecules in protein library technology, such as phage display technology, diagnostic and therapeutic systems, such as human gene therapy and imaging. The trimeric polypeptides being constructed as a monomer polypeptide construct comprising at least one tetranectin trimerising structural element (TTSE) which is covalently linked to at least one heterologous moiety, said TTSE being capable of forming a stable complex with two other TTSEs; or as an oligomer which is comprised of two monomer polypeptide constructs as mentioned above, and which comprises three TTSEs or a multiplum of three TTSEs, or which is comprised of three monomer polypeptide constructs. | 01-28-2010 |
| 20100036100 | T CELL PROTEINS AND NUCLEOTIDES ENCODING THE SAME - The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for detection and treatment of certain autoimmune and inflammatory diseases including asthma. | 02-11-2010 |
| 20100048876 | CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION - The present invention relates to a chromatography ligand, which comprises Domain C from | 02-25-2010 |
| 20100056757 | CLARIFICATION OF TRANSGENIC MILK USING DEPTH FILTRATION - Processes and apparati are provided for separating molecules of interest from a mixture by depth filtration (DF). The DF of the invention is useful in the clarification and processing of various feedstreams for the removal of a molecule of interest. According to a preferred embodiment, a transgenic milk feedstream is stabilized and particulate matter such as fat, casein miscelles and bacteria are removed. An aseptic filtration step was also developed to remove any bacteria remaining in a clarified transgenic milk feedstream. | 03-04-2010 |
| 20100056758 | SELECTIVE INHIBITORS OF CB2 RECEPTOR EXPRESSION AND/OR ACTIVITY FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS - The invention relates to the use of a selective inhibitor of CB2 receptor expression and/or for the manufacture of a medicament indented for the treatment and/or the prevention of obesity and obesity-related disorders. | 03-04-2010 |
| 20100063256 | Novel immunoglobulin-binding proteins with improved specificity - The present invention relates to modified immunoglobulin-binding proteins, e.g., | 03-11-2010 |
| 20100063257 | Purification of FC-TACI Fusion Proteins Using the Oilbody Technology - The invention relates to a process for the purification of Fe-fusion proteins such as TACI-Fc using genetically engineered oilbodies expressing protein A. | 03-11-2010 |
| 20100069614 | Antibody producing non-human mammals - Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal. | 03-18-2010 |
| 20100081792 | Ligand - The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target. | 04-01-2010 |
| 20100087630 | Use of XCR1 for Diagnosing or Monitoring of Immune Tolerance - The invention relates to measuring immunological tolerance in T cells. In particular, the invention provides a method for measuring the tolerance status of a T cell sample, comprising the steps of (a) measuring the expression level of XCR1 (also known as GPR5, which is a receptor for Single C Motif-1/Lymphotactin) in a T cell sample, and (b) comparing the measured expression level with a reference value, said reference value being representative of the expression level of XCR1 in a control T cell sample. The present invention furthermore provides methods, kits and uses to determine the required stringency of immunosuppression, particularly the required dosage of an immunosuppressant. Also provided are methods and uses to identify or validate inducers or inhibitors of immunological tolerance. | 04-08-2010 |
| 20100105873 | INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTICS - The invention provides method for therapeutic protein drug development that incorporates therapeutic and/or formulation and/or manufacturing considerations in the early screening process. The approach involves screening a plurality of different variants of a domain that have been determined to have the desired therapeutic property to identify one or more variants that have desired therapeutic and/or formulation characteristics, and constructing the full multidomain proteins using the identified domain variants. The present invention also provides a method for determining the shelf life of multidomain proteins in formulations. The method comprises determining a thermal denaturation and/or renaturation curve of a domain of the protein whose unfolding leads to aggregation of the protein in a solution. The method evaluates the shelf life of the multidomain protein based on the denaturation/renaturation curve. The invention also provides methods for engineering multidomain proteins to improve their therapeutic and/or formulation characteristics. | 04-29-2010 |
| 20100113745 | Means and Methods for Influencing the Stability of Antibody Producing Cells - The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines. | 05-06-2010 |
| 20100113746 | PROCESS FOR PURIFICATION OF IMMUNOGLOBULINS USING A PSEUDOBIOAFFINITY ADSORBENT - The present invention relates to the development of pseudobioaffinity adsorbent and process for purification of immunoglobulin G from immunoglobulin containing solutions such as but not limited to plasma, serum, cell culture supernatant, ascites fluids. The adsorbent consists of a solid support and ligand. The ligand may be attached to the matrix or be part of matrix. The ligand is selected from a group of hydrophobic amino acids such as alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan and tyrosine and the support material being preferably a synthetic hydrophilic polymer of methacrylate or acrylate species, or any of its derivatives. The adsorbent is cheap and stable to harsh conditions such as 1.0 M NaOH used during regeneration of adsorbents. Moreover there is no problem of toxic leachables typically associated with biological ligands. The nature of the adsorbent also allows high flow rate operations at relatively low pressures. The process includes adjusting the pH and conductivity of the feed solution and the use of ionic salts and additives such as polyols or alcohols for eluting the bound IgG. | 05-06-2010 |
| 20100130727 | Methods and Systems for Isolating Target Molecules from Complex Solutions by Column-Chromatography Using Eluants Containing Organic Solvents - Various system and method embodiments of the present invention are directed to separating target molecules from complex solutions by affinity column chromatography using organic-solvent-containing eluants. In one embodiment of the present invention, an eluant containing an organic-solvent is used, at a first pH, to remove non-target solutes and suspended entities from an affinity chromatography column. The pH of the eluant is then changed to a second pH, and the organic-solvent-containing eluant is used to elute target molecules from the affinity column chromatography. | 05-27-2010 |
| 20100145022 | Method of Isolating Biomacromolecules Using Low pH and Divalent Cations - The present invention is related to a method of isolating a biological macromolecule in a composition. Specifically, the present invention is directed to a method of isolating a biomacromolecule in a composition containing an impurity, the method comprising (a) lowering the pH of the composition, (b) adding a divalent cation to the composition, and (c) separating the biomacromolecule from the impurity. | 06-10-2010 |
| 20100145023 | Optimized Nucleotide Sequences of VB6-845 For Expression of Recombinant Proteins - An optimized nucleic acid sequence encoding the immunoconjugate VB6-845 is described Modifications to the original VB6-845 include changes in the nucleic acid sequence encoding the V | 06-10-2010 |
| 20100152425 | Material for Separation of a Biomolecule - A Product is described and which contains at least one type of ligand bound to a separation material and which allows selective binding or cleavage of a biomolecule for example in human blood. | 06-17-2010 |
| 20100168392 | EXPRESSION OF FULL LENGTH IGG AND SECRETION INTO THE CULTURE MEDIUM OF PROKARYOTIC CELLS - A method for the production of an immunoglobulin or a functional fragment thereof in a prokaryotic host cell comprises transforming the host cell with (a) a first nucleic acid molecule comprising a nucleic acid sequence encoding a V | 07-01-2010 |
| 20100184957 | POROUS BASE MATRIX HAVING FORMYL GROUP, ADSORBENT USING THE POROUS BASE MATRIX, METHOD FOR PRODUCTION OF THE POROUS BASE MATRIX, AND METHOD FOR PRODUCTION OF THE ADSORBENT - The present invention relates to a porous base matrix having formyl group, which base matrix has a structure represented by the formula (2) as a spacer, which structure is obtained by cleaving a group represented by the formula (1): | 07-22-2010 |
| 20100190961 | PROCESS FOR THE PURIFICATION OF FC-CONTAINING PROTEINS - The invention relates to a process for reducing the concentration of free Fc-moieties in a fluid comprising an Fc-containing protein comprising a cation exchange chromatography step. | 07-29-2010 |
| 20100197894 | METHOD AND APPARATUS FOR MATERIAL SEPARATION USING ACOUSTIC ENERGY - A method and apparatus for exposing a sample, including a liquid and another material, to sonic energy to produce a desired result such as, suspending a material support in the liquid. The material support may be a bead or other particle with at least one surface feature to which the material may bind. Material in the liquid may attach to the material support, such as by specific or non-specific binding, entrapment or other, so as to facilitate separation of the material from the liquid. Separation of the material supports from the liquid and other unbound material may be done by allowing the material supports to settle out, e.g., under the force of gravity and/or as assisted by centrifugation, by applying a magnetic field in case the supports or material bound to the supports are movable by way of a magnetic field, or other techniques. | 08-05-2010 |
| 20100210823 | Method of Preparing Enriched Antibodies for Detecting Mycobacterial Infection - The disclosed technology provides an enriched antibody population, highly specific for an antigen of a surface polysaccharide, from a mycobacterium. In a related embodiment, the antibody is enriched by having been raised in an environment that maintains antigenically active antigen. These antibodies may be used in an immunoreactive environment for detecting the presence of a mycobacterial infection in a sample from a subject. | 08-19-2010 |
| 20100210824 | Method of Identifying Drugs, Targeting Moieties or Diagnostics - The present invention relates to a method for identifying a binding agent or epitope for use in drug design, drug targeting or diagnostics. The method employs contacting and sorting binding agents and cognate epitopes from collections thereof, characterizing the binding agent and cognate epitope, detecting the level or location of the epitope in a sample using the binding agent, and correlating the level or location of the epitope in the sample with the presence or stage of a disease or condition to identify novel drugs, targeting moieties, or diagnostic agents. | 08-19-2010 |
| 20100216974 | BINDING MOLECULES - The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. | 08-26-2010 |
| 20100240871 | Galactose Alpha(1-3) Galactose Compositions - An enzymatic method for synthesizing oligosaccharides comprising a terminal Gal-alpha(1,3)-Gal-beta(1-4)GlcNac is used to produce Fc-containing molecules with certain properties. The methods modify glycoproteins that interact with receptors or are processed in vivo and recognized as unique epitopes. In particular, the glycan groups on a therapeutic antibody capable of interaction with Fc-receptors are modified. | 09-23-2010 |
| 20100249379 | PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS - The current invention reports a method for the recombinant production of a secreted heterologous immunoglobulin in a CHO cell comprising the following steps: i) providing a CHO cell, which is adapted to growth in suspension culture, adapted to growth in serum-free medium, mycoplasma free, and virus free, ii) providing a vector comprising a prokaryotic origin of replication, a first nucleic acid conferring resistance to a prokaryotic selection agent, a second nucleic acid encoding the heavy chain of said heterologous immunoglobulin, a third nucleic acid encoding the light chain of said heterologous immunoglobulin, a fourth nucleic acid conferring resistance to a eukaryotic selection agent, iii) transfecting said CHO cell, wherein said transfecting comprises a) transfecting said CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a first eukaryotic selection agent, b) selecting a CHO cell by growth in cultivation medium containing said first eukaryotic selection agent, c) transfecting said selected CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a second eukaryotic selection agent different to said first eukaryotic selection agent, d) selecting a CHO cell by selected growth in cultivation medium containing said first and said second eukaryotic selection agent, iv) cultivating said transfected CHO cell in a medium in the presence of said first and second eukaryotic selection agent, under conditions suitable for the expression of said second, and third nucleic acid, and v) recovering said secreted heterologous immunoglobulin from the cultivation medium. | 09-30-2010 |
| 20100261886 | PROTEIN PURIFICATION BY CITRATE PRECIPITATION - The invention provides methods for isolating proteins in purified form from mixtures by precipitation with citrate. The methods are advantageous in that they effectively separate a protein from lower molecular weight contaminants, including fragments or portions of the protein. Such methods are particularly useful for purifying antibodies from mixtures containing antibody proteolytic fragments and unpaired chains. | 10-14-2010 |
| 20100311953 | PROCESS FOR PURIFYING PROTEINS - The invention relates to a process for purifying a protein by mixing a protein preparation with a solution having a first salt and a second salt, wherein each salt has a different lyotropic value, and loading the mixture onto a hydrophobic interaction chromatography column. The dynamic capacity of the column for a protein using the two salt combination will be increased compared with the dynamic capacity of the column for either single salt alone. | 12-09-2010 |
| 20100317834 | IgG Immunoglobulin Variants with Optimized Effector Function - The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes. | 12-16-2010 |
| 20100324269 | REFOLDING PROTEINS USING A CHEMICALLY CONTROLLED REDOX STATE - A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/L or higher is disclosed. The method comprises identifying the thiol pair ratio and the redox buffer strength to achieve conditions under which efficient folding at concentrations of 2.0 g/L or higher is achieved and can be employed over a range of volumes, including commercial scale. | 12-23-2010 |
| 20110003971 | MODULATORS AND MODULATION OF THE INTERACTION BETWEEN RGM AND NEOGENIN - This invention relates to drug screening using mammalian repulsive guidance molecules and mammalian Neogenin. In addition, the invention provides for methods of preventing, alleviating or treating various disorders of the nervous system, angiogenic disorders or disorders of the cardio-vascular system and malignancies of different etiology by disrupting the interaction between RGM and Neogenin. | 01-06-2011 |
| 20110015374 | Method for Commercial Isolation of Egg Yolk IgY, Its Product, and Uses of the Product - A method for extraction and purification of IgY from immune avian egg yolk comprising diluting a mixture of liquid egg yolk and liquid egg white in treated water; stirring the diluted mixture to obtain an egg mixture; separating the egg mixture into a first water soluble fraction, an unseparated mixture fraction, and a first separated lipophilic fraction; | 01-20-2011 |
| 20110021755 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 01-27-2011 |
| 20110021756 | METHOD OF MANUFACTURING AN AFFINITY PARTICLE, AFFINITY PARTICLE, AND SEPARATION METHOD - A method of manufacturing an affinity particle includes a step of reacting a particle having a reactive functional group on a surface thereof with a ligand having a functional group having a reactivity with the reactive functional group to bond the ligand to the particle, and a step of reacting the particle to which the ligand is bonded with a surface modifying agent having a functional group represented by a general formula of: | 01-27-2011 |
| 20110046353 | Purification Process for Anitbody Fragments Using Derivatized Triazines as Affinity Ligands - A process for the separation of a fragment antibody from a medium is provided. The process comprises contacting the medium comprising the fragment antibody with a synthetic affinity ligand attached to a support matrix under conditions whereby the fragment antibody binds to the synthetic affinity ligand. The synthetic affinity ligand has the formula (I): wherein Q represent an attachment to a solid support matrix, optionally via a spacer group; A and B are each independently —Y-phenyl or —Y-naphthyl groups substituted with one or more substituents capable of hydrogen bonding, preferably one or more of —OH, —SH or —CO | 02-24-2011 |
| 20110060130 | NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY - The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention. | 03-10-2011 |
| 20110092676 | KIT AND METHOD FOR THE LABELLING OF BIOMOLECULES - The present invention relates to a kit for the labelling of biomolecules bearing reactive amino or hydroxyl groups. The kit consists of a Reagent A and a Reagent B, individually packaged, comprising: a mixture of a carboxylated labelling compound and a tertiary amine (Reagent A); and a coupling reagent (Reagent B). Upon contacting Reagent A with Reagent B, the carboxylated labelling compound is activated in-situ by the coupling reagent (a guanidinium, or uranium salt) in the presence of the tertiary amine. The active form of the carboxylated labelling compound is reacted with a biomolecules bearing reactive amino or hydroxyl groups, with formation of a stable covalent bond between the carboxylated labelling compound and the biomolecule. | 04-21-2011 |
| 20110105724 | NOVEL COMPOUNDS - The present invention relates to neutralizing antibodies (immunoglobulins) which are specific for human IL-8 and bind to as well as neutralize human IL-8. | 05-05-2011 |
| 20110105725 | ANTIBODY PURIFICATION PROCESS - The invention concerns a method for the industrial production of antibodies. | 05-05-2011 |
| 20110118442 | CHROMATOGRAPHY LIGAND - The present invention relates to a chromatography ligand defined by the following formula R | 05-19-2011 |
| 20110130544 | ANTIBODIES WITH DECREASED DEAMIDATION PROFILES - The present invention relates to antibodies with decreased deamidation profiles, and methods for producing antibodies with decreased deamidation profiles. | 06-02-2011 |
| 20110130545 | PROCESS FOR PRODUCING MILK FRACTIONS RICH IN SECRETORY IMMUNOGLOBULINS - The present invention concerns a process for producing compositions that are rich in secretory IgA (S-IgA) by fractionating milk containing S-IgA. Such compositions may be used in particular for treating and/or preventing infections and/or inflammation of the mucosal surfaces, e.g. the gastro-intestinal tract, urogenital tract, respiratory tract, nasal cavity or oral cavity, treating and/or preventing obesity and related diseases, or treating and/or preventing food allergies in subjects in need of such treatment. Briefly stated, the current invention provides a process for producing milk fractions rich in secretory Immunoglobulin A, using one or more microporous membrane filtration steps. A preferred protocol of the present process involves de-fatting, micro-filtration and ultrafiltration-concentration through a number of diafiltration cycles. The process of the invention, apart from the unexpectedly high yields achievable, offers advantages which are of particular interest in view of the scalability, application in existing diary factories and controllability of process parameters influencing the S-IgA quality and stability. | 06-02-2011 |
| 20110160436 | METHOD TO SCREEN HIGH AFFINITY ANTIBODY - The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (II) to (XIII) at least the thermodynamic parameters (i) standard association binding entropy formula (A), (ii) standard dissociation binding entropy formula (B), (iii) standard binding entropy (ΔS°), (iv) free standard binding enthalpy (ΔG°), (v) standard dissociation free binding enthalpy formula (C), (vi) standard association free binding enthalpy formula (D), (vii) −TΔS°, (viii) dissociation rate constant k | 06-30-2011 |
| 20110166326 | FILTRATION METHOD - Provided is a filtration method for the step of removing viruses in a process of producing a protein preparation during which an intermediate protein preparation with a high protein concentration flows at high pressure to a virus removal filter. The filtration method employs a virus removal filter which has a close fitting nozzle of which the inlet at least has a pressure resistance of 600 kPa or more, and an effective area of the virus removal membrane of at least 0.0001 m | 07-07-2011 |
| 20110166327 | APHERESIS DEVICE - The invention relates to an apharesis device for use in the treatment of Alzheimer patients. Said device comprises a solid support with which a flow of blood or plasma can be contacted. | 07-07-2011 |
| 20110166328 | Avian Antibodies Specific to Influenza Virus and Technologically Simple Methods of Their Manufacture and Use - Avian antibodies that bind to influenza virus are provided. The disclosed antibodies are inexpensive to produce and are more effective than previously used antibodies against influenza. The present disclosure provides methods of treatment, prevention and diagnosis using such avian antibodies as well as methods of producing the disclosed avian antibodies. Methods of using the disclosed avian antibodies to prevent viral adhesion of influenza to cells are also provided. A novel source of such antibodies is bird eggs from countries in which vaccination against influenza of various bird populations is legally required. The present disclosure solves the problem of the limited supply of antibodies for the diagnosis, treatment, and prevention of influenza. | 07-07-2011 |
| 20110178276 | SURFACE NEUTRALIZATION OF APATITE - The present invention discloses methods of neutralizing apatite surfaces, for example during chromatography and before protein elution. | 07-21-2011 |
| 20110201785 | METHOD FOR OPTIMIZING PROTEINS HAVING THE FOLDING PATTERN OF IMMUNOGLOBULIN - The invention relates to a method for optimizing the biophysical properties of molecules and derivatives of the Ig superfamily. The method is characterized in that as yet unrecognized helical structural elements with unknown structural, stability and folding roles have been identified as important determinants of correct and efficient structuring of antibody domains. The novel process for positively influencing the antibody properties and properties of other proteins that have the Ig folding pattern now consists of optimizing the properties of the short helical elements and in the transplantation of these elements between Ig domains. | 08-18-2011 |
| 20110207916 | Dual Affinity Polypeptides for Purification - The present invention relates to a process for purification of a target biomolecule, comprising the steps: (a) contacting (i) a target biomolecule, (ii) a dual affinity polypeptide, and (iii) a solid support comprising a catching ligand, wherein the ratio between the equilibrium dissociation constants of the dual affinity polypeptide, [K | 08-25-2011 |
| 20110213125 | Humanized Antibodies Against Human Interferon-Alpha - The present invention provides humanized anti-human IFN-α monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof. | 09-01-2011 |
| 20110213126 | TWO-STAGE ULTRAFILTRATION/DIAFILTRATION - The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a (two-stage ultrafiltration/diafiltration approach. | 09-01-2011 |
| 20110218327 | METHOD FOR PROVIDING A .beta.-LACTOGLOBULIN PRODUCT AND AN a-ENRICHED WHEY PROTEIN ISOLATE - The present invention relates to isolation of whey proteins and the preparation of a whey product and a whey isolate. In particular the present invention relates to the isolation of a β-lactoglobulin product and the isolation of an α-enriched whey protein isolate from whey obtained from an animal. The α-enriched whey protein isolate provided by the present invention is besides from being low in β-lactoglobulin also high in α-lactalbumin and immunoglobulin G. | 09-08-2011 |
| 20110257370 | IMMUNOGLOBULIN PURIFICATION - The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an immunoglobulin in monomeric, in aggregated, and in fragmented form to an anion exchange chromatography material under conditions whereby the immunoglobulin in monomeric form does not bind to the anion exchange material, and recovering the immunoglobulin in monomeric form in the flow-through from the anion exchange chromatography material, whereby the buffered aqueous solution has a pH value of from 8.0 to 8.5. In one embodiment the anion exchange chromatography material is a membrane anion exchange chromatography material. | 10-20-2011 |
| 20110301330 | CELLULOSE GEL FOR PURIFICATION OF IMMUNOGLOBULIN - The present invention provides a chromatography packing material having improved flow rate characteristics and adsorption characteristics. In particular, the present invention provides a chromatography packing material suitable for separation and purification of immunoglobulin in the manufacture of antibody preparations. A porous cellulose gel, which is made by adding polysaccharides having a limiting viscosity of 0.21 to 0.90 dL/g to porous cellulose particles, the dry weight per unit volume of the porous cellulose gel being 1.06 to 1.40 times the dry weight per unit volume of the porous cellulose particles, is used. By adding a predetermined amount of polysaccharides having a predetermined limiting viscosity to porous cellulose particles, flow rate characteristics and adsorption characteristics can be improved. | 12-08-2011 |
| 20120016106 | ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES IN TREATMENT OF ALS AND OTHER GDF-8 ASSOCIATED DISORDERS - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 01-19-2012 |
| 20120029171 | Method of Producing a Plurality of Isolated Antibodies to a Plurality of Cognate Antigens - The present invention relates to a method for producing high affinity antibodies that are antigen-specific. The method involves binding a plurality of antibody-producing B-cells from a mammal to a plurality of cognate antigens; sorting the bound antibody-producing B-cell and cognate antigen; amplifying nucleic acid sequences encoding each antibody, or fragment thereof, from the B-cells; and expressing the each antibody in a protein expression system. Antibodies produced in this manner are useful in diagnostic and therapeutic applications. | 02-02-2012 |
| 20120077961 | ENHANCED PURIFICATION OF ANTIBODIES AND ANTIBODY FRAGMENTS BY APATITE CHROMATOGRAPHY - Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed. | 03-29-2012 |
| 20120108794 | Formyl Group-Containing Porous Support, Adsorbent Using Same, Method For Producing Same, and Method For Producing The Adsorbent - The present invention relates to a method for producing a formyl group-containing porous base matrix, comprising the steps of introducing a spacer in a formyl group-containing porous particle; and then oxidizing the spacer with periodic acid and/or a periodate, to transform the part of the spacer into a formyl group; wherein the formyl group content in the porous particle after introduction of the spacer is not more than 3 μmol per 1 mL of the porous particle. Also, the present invention relates to a method for producing an adsorbent, comprising the step of immobilizing an amino group-containing ligand on the formyl group-containing porous base matrix. According to the present invention, a formyl-group containing porous base matrix and an adsorbent produced from the porous base matrix of which adsorption amount is high and which is has high strength and of which ligand is difficult to be leaked are provided. | 05-03-2012 |
| 20120157662 | MEANS AND METHODS FOR PRODUCING HIGH AFFINITY ANTIBODIES - The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells. | 06-21-2012 |
| 20120178909 | Novel Screening Strategies for the Identification of Binders - The present invention discloses novel screening strategies for the identification of binders that target the active site of enzymatic antigens. The present invention also discloses antigen-binding moieties which bind to the NS2B-NS3 Proteinase of West Nile Virus, in particular binders which bind to the active site, thereby inhibiting the enzymatic activity of the proteinase. The antigen-binding moieties of the present invention have numerous therapeutic and diagnostic applications. | 07-12-2012 |
| 20120202974 | PROCESS FOR THE PURIFICATION OF FC-CONTAINING PROTEINS - The invention relates to a process for the purification of an Fc-containing protein based on cation exchange chromatography. | 08-09-2012 |
| 20120253016 | ANTIBODY MOLECULES THAT BIND TO IL-6 RECEPTOR - The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions. | 10-04-2012 |
| 20120259094 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION - The present invention relates generally to affinity ligands and chemical affinity ligand-matrix conjugates for use as chromatographic adsorbents and methods which utilise the adsorbents in the purification of proteins by affinity chromatography. The affinity ligand-matrix conjugates of the present invention comprise ligands of general formula (I): wherein m represents an integer from 0-2, n represents an integer from 0-6, p represents an integer from 0-4, R | 10-11-2012 |
| 20120264915 | CHROMATOGRAPHY PURIFICATION OF ANTIBODIES - Methods, kits and apparatuses for chromatography purification of antibodies are provided. In some embodiments, antibodies are purified by mixed mode chromatography that does not comprise hydroxyapatite (HT) or fluorapatite (FT). The mixed mode chromatography step is then followed by a HT/FT chromatography step. | 10-18-2012 |
| 20120264916 | Methods of Preventing and Removing Trisulfide Bonds - The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein. | 10-18-2012 |
| 20120271040 | MAMMALIAN EXPRESSION VECTOR - The invention provides vector nucleic acid for expressing at least one polypeptide of interest in a mammalian cell, comprising
| 10-25-2012 |
| 20120316323 | NEW PROCESS FOR THE INDUSTRIAL-SCALE PURIFICATION OF GAMMA GLOBULINS FROM HUMAN PLASMA FOR INDUSTRIAL APPLICATIONS - The invention relates to a novel, industrial-scale process for the purification of gamma-immunoglobulins (IgG) starting from plasma or fractions thereof. The method involves two chromatographic steps, i.e. a cation exchange capture chromatography, and then a polishing anion exchange chromatography, ensuring a highly purified end product, which contains no aggregates, and high yields. The process also involves a virus inactivation step by means of a solvent/detergent treatment to inactivate the viruses with a lipid envelope, and a virus removal step by nanofiltering to ensure the removal of the non-enveloped viruses. | 12-13-2012 |
| 20120322981 | CITRULLINATION-SPECIFIC PHAGE DISPLAY - The invention relates to a modified phage display that allows the specific detection of citrullinated proteins. More specifically, the invention relates to a method for citrullinating proteins displayed by phage, without losing phage infectivity, and the detection of those proteins by biopanning. In a preferred embodiment, the phage is a T7 phage. | 12-20-2012 |
| 20130005948 | METHOD FOR PURIFYING POLYPEPTIDE SOLUTIONS - Herein is reported a method for purifying cell cultivation supernatants either directly after fermentation or after one or more preliminary purification steps, such as protein A affinity chromatography. By adjusting the pH value in the acid range and subsequent incubation of the acidified solution host cell nucleic acid and host cell protein can be precipitated but the target polypeptide remains in solution. Thereafter the precipitate and therewith the contaminating host cell components can be removed by a simple physical separation step. | 01-03-2013 |
| 20130012688 | Method for Separating Fractions of Avian Eggs Exclusively Containing IgA and IgM Antibodies - The present invention provides the method of obtaining IgA and IgM antibodies from chicken egg whites. The method involves separating chicken egg whites into two fractions which contain IgA and IgM antibodies exclusively. This separation method consists of raising the volume of the egg whites using purified water, lowering the pH of said volume, filtering the IgM fraction from said volume, precipitating the IgA fraction from the remaining volume, dialyzing the IgA fraction and drying the IgA and IgM fractions. | 01-10-2013 |
| 20130018173 | Identifying Affinity-Matured Human Antibodies - Antigen-specific immunoglobulin V-regions are identified from a library of nucleic acids amplified using polymerase chain reaction using leader sequence-specific forward primers. The use of leader sequence primers allows all V-region sequences to be amplified (including those with extensive 5′ end mutations) without loss of the original 5′ V gene segment sequence. A second V-region library is made using a larger than conventional set of 5′ V-region primers. The sequence errors introduced into the amplification products by this method are corrected using sequence information obtained in the products amplified by the V-region primers to screen the library created using the leader sequence primers. Amino acid sequence information from fragments of donor immunoglobulins can be used to assist in the identification of nucleic acids encoding the heavy and light chains of donor antibodies as well as to design primers to amplify such nucleic acids. | 01-17-2013 |
| 20130023650 | FILLER FOR AFFINITY CHROMATOGRAPHY - Provided is a filler for affinity chromatography which is useful for protein purification and contains porous particles that have a high dynamic binding capacity for proteins and excellent pressure characteristics. The filler for affinity chromatography of the present invention is characterized in that it includes a porous particle consisting of a polymer of vinyl monomer including a cross-linkable vinyl monomer that contains hydroxyl group but does not contain epoxy group and an epoxy group-containing non-cross-linkable vinyl monomer, or a cross-linkable vinyl monomer that contains hydroxyl group and epoxy group, ligands bound to the porous particle, and ring-opened epoxy groups. | 01-24-2013 |
| 20130030154 | MIXED MODE LIGANDS - Substrates comprising a solid support, a ligand, and a linker comprising at least one C, O, N, or S atom covalently connecting the solid support to the ligand, are disclosed, along with methods of using and making the substrates, and devices including the substrates. | 01-31-2013 |
| 20130041135 | FILLER FOR AFFINITY CHROMATOGRAPHY AND METHOD FOR ISOLATING IMMUNOGLOBULIN - Provided are a filler for affinity chromatography which has excellent alkali resistance, and a method for isolating immunoglobulin. The filler for affinity chromatography is a filler in which a protein represented by the following formula (1) is immobilized on a carrier. | 02-14-2013 |
| 20130053547 | AGONIST ANTIBODY TO HUMAN THROMBOPOIETIN RECEPTOR - This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, substitutions, additions, or insertions of amino acid residues, and (2) antibody variable regions capable of binding to and activating a human thrombopoietin receptor. The-agonist antibody further induces colony formation at a concentration of 10,000 ng/ml or lower, and has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less. | 02-28-2013 |
| 20130060009 | PROCESS FOR OBTAINING ANTIBODIES - The present disclosure relates to a method for the manufacture of recombinant antibody molecules comprising culturing a host cell sample transformed with an expression vector encoding a recombinant antibody molecule; adding an extraction buffer to the sample; and subjecting the sample to a heat treatment step; wherein the pH of the sample is detected after addition of the extraction buffer, and optionally adjusted, to ensure that the pH of the sample is 6 to 9 prior to the heat treatment step. | 03-07-2013 |
| 20130079499 | FC BINDING PROTEIN AND METHOD FOR MANUFACTURING SAME - Disclosed are: an Fc binding protein having increased stability with respect to heat, acid, and/or alkalinity compared with the wild type; a method for producing same; and a method for specifically isolating protein containing an Fc binding protein binding site using said Fc binding protein as a ligand for affinity chromatography. | 03-28-2013 |
| 20130096280 | METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES - The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof. | 04-18-2013 |
| 20130102760 | Immunoglobulin Preparations Having Increased Stability - The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations. | 04-25-2013 |
| 20130102761 | SOLID PHASE FOR MIXED-MODE CHROMATOGRAPHIC PURIFICATION OF PROTEINS - Proteins are purified by a mixed-mode chromatography system formed by attaching a ligand with cation exchange and hydrophobic functionalities to a large-pore support matrix, the only linkage between the ligand and the support matrix being a chain having a backbone of no more than three atoms between the hydrophobic group and the support matrix. | 04-25-2013 |
| 20130109838 | METHOD OF ALTERING THE BINDING SPECIFICITY OF PLASMA PROTEINS BY OXIDATION-REDUCTION | 05-02-2013 |
| 20130116413 | PURIFICATION OF PROTEINS - The invention describes a method for protein purification. More particularly, the invention relates to a purification process comprising protein A chromatography and anion exchange chromatography wherein protein A chromatography eluate is further purified by anion exchange chromatography at similar pH or at a pH less than or equal to 6. | 05-09-2013 |
| 20130123470 | METHOD FOR PREPARING SUGAR CHAINS FROM ANTIBODIES - A method allowing easy and quick preparation of sugar chains of antibodies is provided. Sugar chains are cut off from the antibodies in a state where the antibodies are kept being bonded to an absorbing materials, such as the Protein A or the Protein G. Then, the cut off sugar chains are captured to sugar-chain-capturing solid-phase carriers having a functional group that forms a stable bonding with the sugar chains by reacting specifically with the aldehyde groups of the sugar chains. Then, the captured sugar chains are re-released. Sugar chain samples suitable for mass spectrometry, chromatography, or electrophoresis can be prepared easily and quickly by the present method. | 05-16-2013 |
| 20130131318 | SINGLE UNIT ANTIBODY PURIFICATION - The present invention relates to a method for the purification of antibodies from a protein mixture produced in a bioreactor, at least comprising the steps of intermediate purification and polishing, wherein the intermediate purification and polishing step comprises in-line anion exchange chromatography (AEX) treatment and hydrophobic interaction chromatography (HIC) treatment in flow through mode. The present invention further relates to a single operational unit comprising both an anion exchange chromatography part and a hydrophobic interaction chromatography part, which are serially connected, wherein the unit comprises an inlet at the upstream end of the anion exchange chromatography part and an outlet at the downstream end of the hydrophobic interaction chromatography part and wherein the unit also comprises an inlet between the anion exchange chromatography part and the hydrophobic interaction chromatography part. | 05-23-2013 |
| 20130184438 | MUTANT PROTEIN - The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine. | 07-18-2013 |
| 20130197196 | PROTEIN PRODUCTION - The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport. | 08-01-2013 |
| 20130197197 | Chromatographic Method For Purifying FC-Containing Proteins - The present invention relates to methods of depleting impurities, in particular host cell proteins (HCP) and DNA from cell culture supernatants by means of protein A chromatography using a novel washing buffer. | 08-01-2013 |
| 20130203962 | IMMUNOGLOBULIN G FC REGION BINDING POLYPEPTIDE - An immunoglobulin G Fc region binding polypeptide is provided, consisting of an amino acid sequence selected from i) and an amino acid sequence which has at least 95% identity thereto. Also provided are methods for producing the polypeptide, compositions comprising the polypeptide, polynucleoties encoding the polypeptide, multimers of the polypeptide, and methods of using the polypeptide. | 08-08-2013 |
| 20130267684 | METHOD FOR PREPARING AQUEOUS SOLUTION CONTAINING CULTURE MEDIUM AND CHELATING AGENT - Provided are a method for preparing a highly versatile aqueous solution having remarkably improved membrane filterability, which can be stably membrane-filtered in a short time, an aqueous solution prepared by the preparation method, a method for culturing cells using the aqueous solution which is prepared by the preparation method, a method for producing a physiologically active substance using the culturing method, a physiologically active substance produced by the method for producing a physiologically active substance, a method for performing membrane filtration of the aqueous solution which is prepared by the preparation method of the aqueous solution, a method for improving membrane filterability of the aqueous solution, and a method for producing the physiologically active substance by preparing the aqueous solution, performing membrane filtration of the aqueous solution, and then culturing cells using the resulting aqueous solution. The present invention relates to a method for preparing an aqueous solution, characterized by addition of a chelating agent. | 10-10-2013 |
| 20130289247 | SINGLE UNIT ION EXCHANGE CHROMATOGRAPHY ANTIBODY PURIFICATION - The present invention relates to a method for the purification of antibodies from a protein mixture produced in a bioreactor, at least comprising the steps of intermediate purification and polishing, wherein the intermediate and polishing step comprises in either order in-line anion exchange chromatography (AEX) chromatography and cation exchange chromatography (CEX) chromatography steps in flow-through mode. The present invention further relates to a single operational unit comprising both an anion exchange chromatography part and a cation exchange chromatography part in either order, which are serially connected, wherein the unit comprises an inlet at the upstream end of the first ion exchange chromatography part and an outlet at the downstream end of the second ion exchange chromatography part and wherein the unit also comprises an inlet between the first ion exchange chromatography part and the second ion exchange chromatography part. | 10-31-2013 |
| 20130296535 | High-Throughput Immune Sequencing - Methods and compositions for determining and/or monitoring the immune state of an individual are provided. | 11-07-2013 |
| 20130303732 | METHOD FOR USING LIGHT SCATTERING IN REAL TIME TO DIRECTLY MONITOR AND CONTROL IMPURITY REMOVAL IN PURIFICATION PROCESSES - The invention provides a method for controlling contaminants in biopharmaceutical purification processes by using light scattering and UV absorbance to establish a determinant. The invention makes use of multi-angle light scattering (MALS) and UV as a continuous monitoring system to provide information about the elution peak fractions in real-time instead of conventional pooling methods that rely on a predetermined percent UV peak max value to initiate the pooling process; regardless of product quality. | 11-14-2013 |
| 20130317198 | Tandem Purification of Proteins - The present disclosure provides methods for purifying products from a fluid. In some embodiments, provided purification methods use a combination of purification modes (e.g., protein A and ion exchange) operated in tandem, wherein at least one of the modes utilizes weak partitioning. In some embodiments, provided purification methods operate under robust conditions in which a degree of binding between a product and resin is maintained despite variations in operating parameters. | 11-28-2013 |
| 20130331552 | MEANS AND METHODS FOR PRODUCING HIGH AFFINITY ANTIBODIES - Described are means and methods for producing high-affinity antibodies against an antigen of interest, using stable B-cell cultures. | 12-12-2013 |
| 20140039161 | METHOD FOR EXTRACTING IgY (r-LIVETIN) FROM EGG YOLK - A method for extracting IgY (γ-livetin) from yolk is disclosed, which comprises the following steps: (A) providing a buffer solution, a yolk sample, and an inorganic salt solution; (B) diluting the yolk sample with the buffer solution to obtain a mixture, stirring the mixture for a predetermined time, and performing a centrifugation on the mixture to obtain a supernatant; and (C) adding the inorganic salt solution into the supernatant to salt out IgY, wherein a pH value of the buffer solution is in a range from 4.6 to 5.4, a salt concentration of the buffer solution is in a range from 0.05 M to 0.15 M, and a saturation degree of the inorganic salt solution is in a range from 30% to 60%. | 02-06-2014 |
| 20140046029 | SOLID SUPPORT WITH A GRAFTED CHAIN - Articles that contain a solid support with a grafted chain extending from the solid support, methods of making these articles, and various uses of the articles are described. More specifically, the grafted chain has a functional group that can react with or interact with target compound. Alternatively, the functional group on the grafted chain can react with a modifying agent to provide another group that can react with or interact with the target compound. The grafted chains are attached to the solid support through a ring-opened azlactone group. The articles can be used to purify the target compound or to separate the target compound from other molecules in a sample. | 02-13-2014 |
| 20140066598 | Modified Amino Acids - Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis. | 03-06-2014 |
| 20140073766 | METHODS FOR PURIFYING IgY ANTIBODIES - A method for purifying IgY antibodies is provided. The method comprises precipitating IgY antibodies from a sample by contacting the sample with a precipitating agent; and differentially precipitating the IgY antibodies obtained in step (a) using the same or different precipitating agent to separate IgY(Fc) and IgY(ΔFc) antibodies. | 03-13-2014 |
| 20140081000 | Ion Exchange Chromatography with Improved Selectivity for the Separation of Polypeptide Monomers, Aggregates and Fragments by Modulation of the Mobile Phase - Herein is reported a method for producing a polypeptide in monomeric form comprising the following step: recovering the polypeptide in monomeric form from an ion exchange chromatography material by applying a solution comprising a non-ionic polymer and an additive. | 03-20-2014 |
| 20140081001 | Dual Affinity Polypeptides for Purification - The present invention relates to a process for purification of a target biomolecule, comprising the steps: (a) contacting (i) a target biomolecule, (ii) a dual affinity polypeptide, and (iii) a solid support comprising a catching ligand, wherein the ratio between the equilibrium dissociation constants of the dual affinity polypeptide, [K | 03-20-2014 |
| 20140100358 | ANTIBODY PRODUCTION METHOD - Provided is an antibody production method whereby it is possible to repeatedly acquire antibodies produced by fish without killing the fish. Specifically provided is an antibody production method whereby it is possible to repeatedly acquire the antibodies produced by a fish, without killing the fish, by administering antigens to fish that have blisters. | 04-10-2014 |
| 20140107321 | PURIFICATION OF ANTIBODIES - The invention provides a method of purification of antibodies using chromatographic technique. The method involves the use of cation-exchange chromatography for the purification of the antibody. The purified antibody can be used as a therapeutic composition. | 04-17-2014 |
| 20140142286 | CELL CULTURE PROCESS - A method for producing recombinant polypeptides, including antibodies, having targeted levels of carboxyl terminal (C-terminal) lysine or arginine residues is presented. The method involves culturing cells expressing said polypeptides in cell culture medium having sufficient levels of lysine, arginine, and/or agents that change intracellular pH. Culturing the cells under such conditions does not affect cell growth, cell viability, or titer. | 05-22-2014 |
| 20140163208 | COLLECTION AND METHODS FOR ITS USE - The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs. | 06-12-2014 |
| 20140187749 | SINGLE UNIT CHROMATOGRAPHY ANTIBODY PURIFICATION - The present invention relates to a method for the purification of antibodies from a protein mixture produced in a bioreactor, at least comprising the steps of intermediate purification and polishing, wherein the intermediate and polishing step comprises in-line anion exchange chromatography (AEX) treatment and mixed mode chromatography (MiMo) treatment in flow through mode. The present invention further relates to a single operational unit comprising both an anion exchange chromatography part and a mixed mode chromatography part, which are serially connected, wherein the unit comprises an inlet at the upstream end of the anion exchange chromatography part and an outlet at the downstream end of the mixed mode chromatography part and wherein the unit also comprises an inlet between the anion exchange chromatography part and the mixed mode chromatography part. | 07-03-2014 |
| 20140187750 | METHODS FOR SELECTING PROTEASE RESISTANT POLYPEPTIDES - The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans. | 07-03-2014 |
| 20140206845 | Stable Protein-Containing Preparation Containing Argininamide or Analogous Compound Thereof - Addition of argininamide or valinamide to a highly concentrated antibody solution was found to lead to remarkable stabilization, in particular, stabilization against photostress. | 07-24-2014 |
| 20140221619 | Methods and Compositions for Increasing Protein Production - The disclosure provides methods and materials for increasing the expression of a protein of interest such as an antibody by a cell. ABC50 expression or activity is increased which increases expression of the protein or antibody of interest. The disclosure also provides methods and materials for increasing the sensitivity of a cell to an endoplasmic reticulum stress agent such as Econozole by decreasing the level of ABC50. | 08-07-2014 |
| 20140288272 | ANTIBODY PURIFICATION AND PURITY MONITORING - Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as | 09-25-2014 |
| 20140343255 | TWO-STAGE ULTRAFILTRATION/DIAFILTRATION - The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a two-stage ultrafiltration/diafiltration approach. | 11-20-2014 |
| 20140371427 | IgG2 DISULFIDE ISOFORM SEPARATION - Methods for producing an IgG2 antibody preparation enriched for one of several IgG2 structural isoforms, differing by disulfide connectivity in the hinge region of the antibody, are disclosed. | 12-18-2014 |
| 20150025224 | ANTAGONISTS OF NEUROPILIN RECEPTOR FUNCTION AND USE THEREOF - The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases. | 01-22-2015 |
| 20150073128 | CHROMATOGRAPHY LIGAND - The present invention relates to a chromatography ligand defined by the following formula R | 03-12-2015 |
| 20150080554 | AFFINITY CHROMATOGRAPHY MATRIX - The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine. | 03-19-2015 |
| 20150133636 | Purification of Biological Molecules - The present invention relates to improved processes and systems for purification of biological molecules, where the processes can be performed in a continuous manner. | 05-14-2015 |
| 20150299248 | Multimodal Anion Exchange Matrices - The invention discloses a separation matrix which comprises a plurality of separation ligands, defined by the formula R | 10-22-2015 |
| 20150315265 | SECONDARY ANTIBODY DETECTED EPITOPE AND PREPARATION OF SAME - A method of preparing an epitope for a secondary antibody detected protein tag, comprising: constructing a expressing vector, comprising a nucleotide sequence for encoding the secondary antibody detected protein tag comprising at least one epitope selected from at least one primary antibody which is detected by corresponding secondary antibody; expressing the vector in a host cell; and obtaining the secondary antibody detected protein tag which is expressed in the host cell. Further, a method for constructing a protein molecular weight marker ladder, comprising constructing a plurality of recombinant protein tags with different molecular weights, wherein each the recombinant protein tag comprises at least one epitope of primary antibody. Besides, a secondary antibody detected protein tag comprises at least two peptide sequences of epitopes selected from primary antibodies of at least two different species. | 11-05-2015 |
| 20150329586 | Refolding Proteins Using a Chemically Controlled Redox State - A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/L, or higher is disclosed. The method comprises identifying the thiol pair ratio and the redox butler strength to achieve conditions under which efficient folding at concentrations of 2.0 g/L or higher is achieved and can be employed over a range of volumes, including commercial scale. | 11-19-2015 |
| 20150353598 | ENHANCED PURIFICATION OF ANTIBODIES AND ANTIBODY FRAGMENTS BY APATITE CHROMATOGRAPHY - Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed. | 12-10-2015 |
| 20150361437 | RECOMBINANT YEAST TRANSFORMANT AND PROCESS FOR PREPARING IMMUNOGLOBULIN FC FRAGMENT EMPLOYING THE SAME - The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment into | 12-17-2015 |
| 20160002290 | MATERIALS AND METHODS FOR REMOVING ENDOTOXINS FROM PROTEIN PREPARATIONS - A method includes (i) adding allantoin in a supersaturating amount to a protein preparation including a desired protein and at least one endotoxin as a contaminant, (ii) removing solids after the adding step to provide a sample for further purification by void exclusion chromatography on a packed particle bed of electropositive particles in a column, the packed particle bed having an interparticle volume, (iii) applying a sample volume to the packed particle bed, wherein the electropositive particles support void exclusion chromatography, and wherein the sample volume is not greater than the interparticle volume, and (iv) eluting a purified sample including the desired protein and a reduced amount of the endotoxin. The method is optionally carried out with only the allantoin treatment or only the void exclusion chromatography. | 01-07-2016 |
| 20160009760 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | 01-14-2016 |
| 20160016990 | PROTEIN PURIFICATION BY MEANS OF AQUEOUS TWO-PHASE CENTRIFUGAL EXTRACTION - The invention relates to a method for the selective purification and concentration of immunoglobulins or other proteins by means of an aqueous two-phase system using a centrifugal extractor. | 01-21-2016 |
| 20160018415 | MARKER FOR DIAGNOSING DIABETIC RETINOPATHY AND USE THEROF - The present invention relates to a marker which can be used to diagnose a diabetic retinopathy patient and determine the progression of diabetic retinopathy, a composition for diagnosing diabetic retinopathy, which comprises an agent for measuring the level of a gene or protein associated with the marker, and the use thereof. | 01-21-2016 |
| 20160032280 | METHODS FOR THE PRODUCTION OF LIBRARIES FOR DIRECTED EVOLUTION - Disclosed herein is an efficient method of generating a library of variants of a sequence of interest, such as may be used in directed evolution, in one embodiment, the method includes an amplification reaction, e.g. error-prone PCR, to generate double-stranded DNA (dsDNA) variants of a sequence of interest, after which one strand of the dsDNA variants may be selectively degraded to produce single-stranded DNA (ssDNA) variants. The ssDNA variants may be hybridized to ssDNA intermediaries, e.g., uracilated circular ssDNA intermediaries, to form heteroduplex DNA, which may be transformed into cells, such as | 02-04-2016 |
| 20160052961 | SURFACE NEUTRALIZATION OF APATITE - The present invention discloses methods of neutralizing apatite surfaces, for example during chromatography and before protein elution. | 02-25-2016 |
| 20160108127 | Methods of Controlling the Formation of Disulfide Bonds in Protein Solutions - Disclosed herein are methods that have been developed to control the formation of disulfide bonds between polypeptides of a multimeric protein produced by a bioprocess. Also disclosed are protein solution parameters that allow for controlling the formation of disulfide bonds. In one example, the methods disclosed herein can be used to control the proportion of half antibody molecules in an antibody solution. | 04-21-2016 |
| 20160115194 | PROTEIN PURIFICATION PROCESS - A method of purifying a target protein includes contacting a cell culture harvest or a protein preparation including at least one target protein with at least one fatty acid having 8 to 10 carbon atoms to form a mixture, contacting the mixture with one or more solids to form a mixture, the one or more solids comprise a cationic functional group, a metal binding functional group, or both, the metal binding functional group including a nitrogen-containing moiety selected from (1) a polyamine, (2) an imine, (3) an N-heterocycle, (4) an amino acid, (5) an N-hydroxyamide, (6), an arylamine, and combinations thereof, and separating solid materials after contacting the mixture with the one or more solids to provide a solution comprising the target protein. | 04-28-2016 |
| 20160159857 | Mutated Immunoglobulin-Binding Polypeptides - The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of | 06-09-2016 |
| 20160200797 | Chromatography Ligand Comprising Domain C From Staphylococcus Aureus Protein A For Antibody Isolation | 07-14-2016 |
